Leukemia is a hematological malignancy that involves bone marrow. Polymorphism of biotransformation genes plays an important role in primary childhood leukemia and affects the incidence and character of acute leukemia relapse. A biochip designed to assess some polymorphisms of biotransformation genes was used to determine the frequency of the polymorphic variants of CYP1A1, CYP2D6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, CYP2C9, CYP2C19 and NAT2 in 332 children with acute lymphoblastic leukemia (ALL) and 71 children with acute myeloblastic leukemia (AML). The CYP1A1 *1/*2A, GSTT1 non null and GSTM1 non null genotypes were more frequent in patients with primary leukemia than in relapse. Analysis of the NAT2 genotype frequency revealed a characteristic genotype for each type of leukemia, which prevailed in patients with relapse: the genotype 341C/-, 481T/-, 590G/G, 857G/G prevailed in ALL patients with relapse, and the genotype 341T/T, 481C/C, 590A/-in AML patients with relapse when compared with patients having primary ALL or AML, respectively. Thus, the polymorphisms of CYP1A1, GSTT1, GSTM1 and NAT2 genes can be considered as markers for risk of relapse in childhood acute leukemia and can be used for the prognosis and individualization of standard therapy.
INTRODUCTION
Leukemia is a hematological malignancy that involves bone marrow. This disease is socially important, as it is among the major causes of death in children. Acute lymphoblastic leukemia (ALL) is the most common form, accounting for about 80% of all acute leukemia cases. Acute myeloblastic leukemia (AML) accounts for 15% of leukemia cases in children [1, 2] . The causes of the acute leukemias have not yet been identified. The current concept of their etiology and pathogenesis suggests an important role for chromosome aberrations, which may be inherited or induced by external factors [3] .
Childhood acute leukemia is a clinically heterogeneous disease with highly variable response to therapy and prognosis. Almost all current prognostic factors are characteristics of leukemia cells in both primary acute leukemia and in relapse [3, 4] . Individual features of drug metabolism are not pres-
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ently considered during choice of anti cancer therapy. However, several studies have shown that the activities of some drug-metabolizing enzymes can modulate to a considerable extent the individual efficacy of cancer therapy [5, 6] .
All xenobiotics, including therapeutic agents, are degraded and eliminated from the body by a system of enzymes encoded by specific genes. Most of these genes are polymorphic, and some polymorphic forms have a changed activity. The most important are phase I biotransformation enzymes (cytochromes of the P450 family, such as CYP1A1, CYP2D6, CYP2C9, and CYP2C19), which activate xenobiotics to yield genotoxic intermediates, and phase II enzymes [glutathione S-transferases (GSTs), arylamine N-acetyltransferases (NATs), etc.], which convert the genotoxic compounds to non toxic ones [7, 8] . In addition, several genes determine the response to anti cancer drugs. For instance, the products of methylene tetrahydrofolate reductase (MTHFR), methionine synthase reductase (MTRR) and thiopurine-S-methyltransferase (TPMT) genes, participate in metabolism of the anti cancer agents 5-fluorouracil, methotrexate, and thiopurine derivatives [6, 9, 10] .
Polymorphism of phase I and II enzymes play an important role in primary childhood leukemia [8, [11] [12] [13] [14] . Moreover, polymorphisms of the biotransformation genes affect the incidence and features of acute leukemia relapse [6, 10, [15] [16] [17] [18] [19] [20] . Since genotype frequencies vary among populations, it is useful to test the polymorphisms of the xenobiotic detoxification genes for association with the efficacy of therapy.
A biochip that assesses several polymorphisms of biotransformation genes has been designed in our laboratory [7, 21, 22] . It permits assessment of 24 mutations of 11 genes: CYP1A1 (4887С>А, 4889A>G, and 6235T>C), CYP2D6 (1934G>A and DelA2637), GSTT1 (deletion), GSTM1 (deletion), MTHFR (677C>T and 1298A>C), MTRR (66A>G), NQO1 (609C>T), CYP2C9 (430C>T and 1075A>C), CYP2C19 (681G>A), NAT2 (341T>C, 481C>Т, 590G>A, and 857G>A), and ТPМТ (238G>C, 292G>T, 460G>A, 644G>A, 681T>G and 719A>G). The relation of 6-MP therapy to TP-MT-genotype was studied previously and showed that ALL patients with a heterozygous TPMT-genotype were characterized by lower tolerance for standard doses [6, 23] . In the present study, we set out to identify the markers for the prognosis and the efficacy of therapy for children with acute leukemia, in the genetic polymorphisms of key enzymes involved in the metabolism of xenobiotics and anti cancer agents. Using the biochip, we determined the frequency of the polymorphic alleles of CYP1A1, CYP2D6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, CYP2C9, CYP2C19 and NAT2 in 403 children with acute leukemia. After the patients were classified by type of leukemia, the frequency of the allelic variants of the genes were compared in children diagnosed with primary leukemia or with leukemia relapse.
MATERIALS AND METHODS
Patients. We examined 332 children, including 258 diagnosed with primary ALL and 74 with ALL relapse. Their mean age was 6 years (from 3 months to 16 years; 57.8% males). We also examined 71 children with AML, including 41 diagnosed with primary AML and 30 with AML relapse. Their mean age was 8 years (from 1 to 17 years; 47.9% males). All patients were residents of the European part of Russia and originated from the East Slavonic population. The parents of all patients gave their informed consent according to the Declaration of Helsinki; the study was approved by the authorities of the Engelhardt Institute of Molecular Biology, Moscow, Russia. Diagnosis was made according to the 1997 World Health Organization (WHO) classification [23] . Blood/bone marrow specimens were obtained for diagnosis of primary disease, relapse, or remission in the oncohematology divisions of the Russian Children's Clinical Hospital (Moscow), Morozov Children's Clinical Hospital (Moscow), and the Moscow Regional Oncological Dispensary (Balashikha) from 2000 to 2004. The ALL and AML patients received scheduled therapy according to the protocol ALL-MB-02 or AML-2000 (MoscowMinsk), respectively. The drugs administrated are summarized in Table 1 .
Specimens. DNA samples were isolated from whole blood or bone marrow leukocytes, using a Wizard genomic DNA purification system (Promega, Madison, WI, USA).
Oligonucleotide Synthesis and Biochip Preparation. The oligonucleotides to be immobilized in a biochip were synthesized on a 394 automated DNA/ RNA synthesizer (Applied Biosystems, Carlsbad, CA, USA) according to the standard phosphoramidite procedure [24] . The 3' end of the oligonucleotides was linked to a spacer with a free amino group, which was introduced during synthesis with the use of a 3'-Amino-Modifier C7 CPG 500 (Glen Research, Sterling, VA, USA). The nucleotide sequences of the immobilized nucleotides [7, 21] are available on request. Biochips were obtained by photoinducible copolymerization of the oligonucleotides with the components of polyacrylamide gel [25] .
Multiplex Polymerase Chain Reaction (PCR). DNA fragments of all genes were amplified in two rounds of nested multiplex PCR except for the GSTT1 and GSTM1 genes, which were amplified in one round of PCR. The primers were designed using the Oligo 6 program (Molecular Biology Insights, Cascade, CO, USA). The target mutations and the primer sequences [7, 21] are available on request. Five parallel multiplex reactions were run. The primer combinations and the PCR conditions were as described [7, 21] .
The fluorescently-labeled products of the second rounds of multiplex PCR were hybridized to the biochip. The hybridization mixture (30 µL) contained 25% formamide (Serva, Heidelberg, Germany), 5× SSPE (Promega), and the PCR product (3 µL from each multiplex reaction), and denatured at 95°С for 5 min, quickly chilled in ice for 1 min, and applied onto the biochip. The biochip was incubated at 37°С overnight, washed with 1× SSPE at room temperature for 10 min and then dried.
Image Analysis. The fluorescent signal from cells of the microchip was detected using a portable biochip analyzer supplied with a CCD camera and Imageware software (Biochip-IMB, Moscow, Russia) [21] [22] .
Sequencing. Specimens with different polymorphic variants of CYP1A1 were sequenced using a 3100 ABI PRISM™ genetic analyzer (Applied Biosystems).
Statistical Analysis. This was performed using the GraphPad InStat program (San Diego, CA, USA). Genotype frequency distributions were tested for correspondence to the Hardy-Weinberg equilibrium by the χ2 test and proved to obey it for all biotransformation genes. For each genotype we estimated odds ratios (OR) and 95% confidence intervals (95% CI). The OR value is widely adopted in epidemiological studies to estimate the probability to have the disease for the carrier of a particular genotype (see also [7] Number of subjects with genotype 1 a c
Number of patients without genotype 1 b d
, where , is that each two values in row and columns are random. The null hypothesis is rejected at critical level of confidence 5%, if the calculated probability
is less than 0.05.
The OR values below are given with a 95% confidence interval; p = 0.05 was used as a threshold to estimate the statistical significance of difference in genotype frequencies.
RESULTS
The biochip addressing the biotransformation gene polymorphisms was used to examine 403 DNAs of children with acute leukemia. The genotype frequencies in children with primary acute leukemia or relapse are summarized in Tables 2 to 11.   7 is less than 0.05.
The biochip addressing the biotransformation gene polymorphisms was used to examine the DNA of 403 children with acute leukemia. The genotype frequencies in children with primary acute leukemia or relapse are summarized in Tables 2 to 11 .
Distribution of CYP1A1 Genotypes. The CYP1A1 genotype frequency was studied in patients with primary leukemia or relapse (Table 2 ). We observed both common (*1/*1, *1/*2A, *1/*2B and *1/*4) and rare allele combinations such as *2B/*4, *2B/*2B, and *2A/*2A). Genotype frequency of the CYP1A1 genotype *1/*2A was higher in patients with ALL or AML relapse than in those with primary acute leukemia (Table 3) . The difference was significant for patients with ALL (OR = 2.29, 95% CI = 1.09-4.80, p = 0.0322). The group of relapsed patients (not separated according to leukemia variant) showed a significant increase in frequency of the CYP1A1 genotype *1/*2A when compared with primary leukemia patients (OR = 2.11, 95% CI = 1.11-4.02, p = 0.0291). Because the CYP1A1 *2A/*2A genotype is very rare (genotype frequency is 0.4 in patients with primary ALL and 0.0 in all other groups), it was not taken into account.
Distribution of GSTT1 Genotypes. An opposite tendency was observed for GSTT1: the null genotype was far less frequent in ALL or AML relapse than in primary leukemia. The difference was significant in the case of ALL (OR = 0.48, 95% CI = 0.26-0.90, p = 0.0227; Table 4 ). The null genotype frequency in patients with relapse (not separated according to leukemia variant) was 1.8-fold less than in primary leukemia patients (OR = 0.55, 95% CI = 0.33-0.92, p = 0.0265).
Combined Analysis of CYP1A1 Genotype *1/*2A and GSTs Genotypes. Patients with ALL and/or AML relapse had a higher frequency of CYP1A1 genotype *1/*2A in combination with the GSTT1 non null genotype, GSTM1 non null genotype, or the double GSTT1/GSTM1 non null genotype when compared with primary leukemia patients ( Table 5 ). The patients with relapse also had a significantly higher frequency of CYP1A1 genotype *1/*2A and the double GSTT1/GSTM1 non null genotype when compared with those with primary leukemia (OR = 3.48, 95% CI = 1.23-9.84, p = 0.0293).
Distribution of NAT2 Genotypes. The NAT2 allele frequency distribution in patients with ALL and AML revealed a characteristic genotype for each type of leukemia, whose presence increases the risk of relapse. Patients with ALL relapse had OR The patients with AML relapse had a lower frequency of heterozygous and homozygous variants 341C/-and 481T/-, and their combination, when compared with primary leukemia patients (data not shown). They also had a higher frequency of the heterozygous and homozygous variant 590A/-when compared with primary leukemia patients. In total, patients with AML relapse had a significantly higher frequency of genotype 341T/T, 481C/C, 590A/-when compared with primary leukemia patients (OR = 2.37, 95% CI = 0.86-6.54, p = 0.125).
Combined Analysis of NAT2 and GSTs Genotypes. The NAT2 genotype 341C/-, 481T/-, 590G/G, 857G/G in combination with the GSTT1 and/or GSTM1 non null genotype occurred in patients with ALL relapse at a significantly higher frequency than in those with primary leukemia (Table 6 ). Patients with AML relapse also displayed a higher frequency of NAT2 genotype 341T/T, 481C/C, 590A/-in combination with the GSTT1 and/or GSTM1 non null genotype when compared with primary leukemia patients. The difference was significant for the com- Table 8 ). Boys with ALL or AML relapse had a lower frequency of the GSTT1 null genotype when compared with boys with primary leukemia. The difference was significant only for ALL (OR = 0.35, 95% CI = 0.15-0.85, p = 0.0163). The frequency of the GSTT1 null genotype in boys with relapse (not separated according to leukemia variant) was 2.7-fold lower than in boys with primary leukemia (OR = 0.37, 95% CI = 0.18-0.79, p = 0.0085). There was a significant increase in frequency of CYP1A1 genotype *1/*2A in combination with GSTT1 non null genotype for boys with ALL relapse when compared with boys with primary ALL (OR = 3.09, 95% CI = 1.17-8.15, p = 0.0254).
Distribution of the CYP1A1 Genotype *1/*2A and GSTs Genotypes in Girls with Acute Leukemia. Combinations of the CYP1A1 Genotype *1/*2A and GSTs Genotypes. Girls with ALL or AML relapse had a higher frequency of CYP1A1 genotype *1/*2A when compared with girls with primary leukemia ( Table 9 ). The patients with ALL or AML relapse had a lower frequency of the GSTM1 null genotype when compared with girls with primary leukemia. The difference was significant only for ALL (OR = 0.37, 95% CI = 0.15-0.90, p = 0.0303). Frequency of the GSTM1 null genotype in girls with acute leukemia relapse (not separated according to leukemia variant) was 2.4-fold lower than in those with primary leukemia (OR = 0.41, 95% CI = 0.19-0.85, p = 0.0175). Girls with leukemia relapse had a higher frequency of the CYP1A1 genotype *1/*2A in combination with the GSTM1 non null genotype when compared with girls with primary leukemia (Table 9) . The NAT2 Genotype Distribution in Girls with Acute Lymphoblastic Leukemia. Girls with ALL relapse had a higher frequency of heterozygous and homozygous variants 341C/-and 481T/-of NAT2 and a lower frequency of heterozygous and homozygous variants 590A/-and 857A/-when compared with these with primary ALL (data not shown). Girls with ALL relapse showed a higher frequency of genotype 341C/-, 481T/-, 590G/G, 857G/G when compared with those with primary leukemia (OR = 1.71, 95% CI = 0.73-4.04, p = 0.267).
The NAT2 Genotype Distribution in Boys with Acute Myoloblastic Leukemia. Boys with AML relapse had a lower frequency of heterozygous and homozygous variants 341C/-and 481T/-of NAT2 and their combinations when compared with those with primary AML (Table 10 ). An opposite tendency was observed for the NAT2 polymorphic variant 590G>A, the frequency of the heterozygous and homozygous variant 590A/-in AML relapse being higher than in primary leukemia. Boys with AML relapse had a higher frequency of genotype 341T/T, 481C/C, 590A/-when compared with those with primary AML (OR = 2.40, 95% CI = 0.55-10.39, p = 0.297). 
DISCUSSION
Our results demonstrate that particular variant alleles of the biotransformation genes are associated with a higher risk of relapse in childhood acute leukemia. Most of the regularities we observed agree with the published data [16] [17] [18] [19] [20] . For instance, the association of polymorphic variant CYP1A1*2A with poor therapeutic prognosis has been shown in children with ALL (OR = 3.08, 95% CI = 1.62-5.88, p = 0.0011) [16] . An increase in frequency of the CYP1A1 genotype *1/*2A in children with ALL relapse can be explained by synthetic glucocorticoids (such as dexamethasone and prednisolone) being an important component of the ALL treatment protocol and in induction therapy. They cause lymphopenia and involution of lymphoid tissue that lead to immunosuppression. Published data demonstrate that they can potentiate the activity of CYP1A1 by action through the glucocorticoid-responsive elements [16, 26] . The presence of a polymorphism in the CYP1A1 gene increases the enzymatic activity and, leads to increased concentration of intermediate genotoxic metabolites and of total mutagenic activity [14, 19] . Since formation of additional mutations may cause resistance of cancer cells towards therapy, it is likely that the CYP1A1 *1/*2A genotype may decrease the efficacy of therapy and promote development of relapse [16] .
We also observed that patients with the GSTT1 and/or GSTM1 null genotype have a lower risk of recurrence when compared with those with one or two functional alleles [17, 18, 20] . The GSTs are involved in metabolism of many anti tumor drugs, catalyzing conjugation of intermediate metabolites with reduced glutathione. In addition, they can determine resistance to chemotherapeutic agents [27] . Thus, ALL children carrying the GSTT1 null genotype have been observed to respond well to induction therapy with prednisone, while carriers of at least one functional GSTT1 allele displayed glucocorticoid resistance, a poor response to therapy, and a higher relapse rate [20] . The total 5-year survival in high-risk ALL has been shown to be substantially higher in children carrying the GSTM1 null genotype than in carriers of the non null genotype (p = 0.03) [17] . Our results suggest that, in carriers of the GSTT1 and/or GSTM1 null genotype, lack of GSTT1 and/ or GSTM1 enzymes leads to an accumulation of cytotoxic drugs, with enhancement of their efficacy and longer relapse-free survival.
The ALL-MB-02 treatment protocol does not include oxazaphosphorines. The cytostatics cyclophosphamide and ifosfamide are widely used for treating ALL according to the ALL-BFM protocol and exert an immunosuppressive effect by inhibiting proliferation of lymphocyte clones involved in the immune response. The GSTs catalyze conjugation of cyclophosphamide with glutathione [28] . Also among children with steroid-dependent nephropathic syndrome, carriers of the GSTM1 null genotype have a far greater relapse-free survival when compared with carriers of one or two functional GSTM1 alleles [29] . Thus, the GSTM1 null genotype improves the efficacy of cyclophosphamide: lack of GSTM1 allows accumulation of the cytotoxic and immonosuppressing metabolite 4-OH-cyclophosphamide which is a substrate of the enzyme GSTM1 [30] .
An important component of induction therapy for ALL is the anthracyclines (e.g., daunorubicin and doxorubicin), which exert an immunosuppressive effect. It has been shown [31] that daunorubicin in vitro causes induction of GSTs, which may account for the resistance to cytotoxic effects. However by increasing the efficacy of the anthracyclines, the GSTs null genotypes may increase the risk of certain adverse reactions. Moreover, among AML patients with the GSTT1 null genotype, those receiving low doses of anthracyclines had a better prognosis than those who received high-dose therapy [32] .
We found that the presence of both the CYP1A1 genotype *1/*2A and the GSTT1 and/or GSTM1 non null genotype has an additive effect on the risk of acute leukemia relapse. The polymorphic variant CYP1A1*2A has been associated with a higher risk of acute leukemia relapse, whereas the GSTT1 and/ or GSTM1 null genotype exerts a protective effect [16] [17] [18] [19] [20] . Our results suggest that therapy is far more effective in patients carrying no CYP1A1*2A allele, increasing CYP1A1 activity, neither GSTT1 and/or GSTM1 functional alleles, where the lack of function favors the accumulation of cytotoxic metabolites and strengthens the therapeutic effect.
The NATs catalyze the addition of the acetyl group to the terminal nitrogen of arylhydrazines and arylamine-containing drugs and carcinogens [33] . The NAT2 is the main acetylating enzyme, while NAT1 acetylates fewer arylamines. Three main slow alleles which cause a slow NAT2 acetylation phenotype: NAT2*5 (T341C, C481T), NAT2*6 (G590A), and NAT2*7 (G857A), and one fast (wild type) allele NAT2*4, form the basis for comparing genetic and biochemical data. A combination of a fast and a slow allele yields an intermediate acetylation phenotype [34, 35] . According to published data, the NAT2 polymorphic variants that determine the slow acetylator phenotype decrease either the activity or the stability of the enzyme. For instance, substitution of C for T at position 341 causes the substitution Ile Glu result in a less stable enzyme [33] [34] [35] [36] .
The NAT2 alleles can modulate the risk of various tumors [37] [38] [39] , including acute leukemia [11] . We observed two characteristic NAT2 genotypes: 341C/-, 481T/-, 590G/G, 857G/G for ALL relapse and 341T/T, 481C/C, 590A/-for AML relapse. Since the intermediate/slow acetylator phenotype occurred at a higher frequency in both cases, the difference in genotype could be determined by the structure of NAT2 substrates. Since methotrexate and cytarabine are aryl and heterocyclic amines they may most probably be substrates for NAT2 [11, 40] (Figure 1 ). Both are employed in acute leukemia: methotrexate for ALL in the consolidation phase, and cytarabine throughout AML therapy. NAT2 may metabolize 6-mercaptopurine ( Figure 1 ) and its analogs used in the ALL therapy, but these are metabolized mainly by thiopurine-S-methyltransferase [6, 22] . Thus, we speculate that the intermediate/slow acylator phenotype promotes accumulation of these drugs and their reactive metabolites in childhood acute leukemia. These metabolites cause multiple chromosome aberrations in bone marrow cells [41, 42] , which, with other adverse factors, lead to relapse.
An interesting finding is that patients with ALL relapse showed a significant increase in the frequency of the NAT2 genotype 341C/-, 481T/-, 590G/G, 857G/G in combination with GSTT1 and/or GSTM1 
